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Abstract
Background: The options for medical use of signaling molecules as stimulators of tissue regeneration are currently limited.
Preclinical evidence suggests that fibroblast growth factor (FGF)-2 can promote periodontal regeneration. This study aimed
to clarify the activity of FGF-2 in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the
safety of such stimulation.
Methodology/Principal Findings: We used recombinant human FGF-2 with 3% hydroxypropylcellulose (HPC) as vehicle and
conducted a randomized double-blinded controlled trial involving 13 facilities. Subjects comprised 74 patients displaying a
2- or 3-walled vertical bone defect as measured $3 mm apical to the bone crest. Patients were randomly assigned to 4
groups: Group P, given HPC with no FGF-2; Group L, given HPC containing 0.03% FGF-2; Group M, given HPC containing
0.1% FGF-2; and Group H, given HPC containing 0.3% FGF-2. Each patient underwent flap operation during which we
administered 200 mL of the appropriate investigational drug to the bone defect. Before and for 36 weeks following
administration, patients underwent periodontal tissue inspections and standardized radiography of the region under
investigation. As a result, a significant difference (p=0.021) in rate of increase in alveolar bone height was identified
between Group P (23.92%) and Group H (58.62%) at 36 weeks. The linear increase in alveolar bone height at 36 weeks in
Group P and H was 0.95 mm and 1.85 mm, respectively (p=0.132). No serious adverse events attributable to the
investigational drug were identified.
Conclusions: Although no statistically significant differences were noted for gains in clinical attachment level and alveolar
bone gain for FGF-2 groups versus Group P, the significant difference in rate of increase in alveolar bone height (p=0.021)
between Groups P and H at 36 weeks suggests that some efficacy could be expected from FGF-2 in stimulating
regeneration of periodontal tissue in patients with periodontitis.
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Introduction
Periodontitis, evoked by the bacterial biofilm (dental plaque)
that forms around teeth, progressively destroys the periodontal
tissue supporting the teeth, including the periodontal ligament,
cementum, alveolar bone and gingiva. Ultimately, this chronic
inflammatory disease can lead to loss of the affected teeth [1–3].
All over the world, this disease remains highly prevalent [4] and is
considered to threaten quality of life (QOL) for middle-aged and
older populations as far as ‘‘oral’’ functions are concerned. Some
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titis by mechanically removing bacterial biofilm, the very cause of
the disease. However, removal of the cause, bacterial plaque, with
conventional periodontal and/or surgical treatments can, at best,
reduce pocket depth and diminish inflammation in the affected
region. No such treatment can ever regenerate lost periodontal
tissue or normal structure and functionality. Considering that the
‘‘mouth’’ and ‘‘teeth’’ have various aesthetic and functional roles
to play, establishing a brand-new treatment that enables the
regeneration and rebuilding of periodontal tissue once destroyed
by periodontal disease represents a task of tremendous impor-
tance.
To regenerate periodontal tissue destroyed by periodontitis, the
chain ofeventsrequiresstimulationofcementoblastsandosteoblasts
into differentiation on the dental root and alveolar bone surfaces
facing the region of periodontal tissue defect, followed by
regeneration of the cementum and alveolar bone. Collagen fascicles
produced by the periodontal ligament fibroblasts should then be
embedded into those regenerated hard tissues, to rebuild new tissue
to support teeth. Researchers have recently confirmed the existence
of mesenchymal stem cells within the periodontal ligament, one of
the cornerstones of periodontal tissue. These stem cells can
differentiate into cells such as cementoblasts and osteoblasts [5].
Using the biological potentials of those stem cells to stimulate the
regeneration of periodontal tissue is now being recognized as
clinically possible. Some researchers are already trying to establish
new treatments to accelerate the regeneration of periodontal tissue
by local application of human recombinant cytokines to stimulate
proliferation and differentiation into hard-tissue forming cells of
undifferentiated mesenchymal cells among periodontal ligament
cells. Direct local application of a combination of factors such as
platelet-derived growthfactor(PDGF)andinsulin-like growthfactor
(IGF)-I [6], bone morphogenetic protein (BMP)-2 [7,8], transform-
ing growth factor (TGF)-b [9], osteogenic protein (OP)-1 [10] and
brain-derived neurotrophic factor (BDNF) [11] to artificial defects
in periodontal tissue made in laboratory animals reportedly
stimulates and promotes regeneration of regional periodontal tissue.
In addition, the efficacy of PDGF-BB plus b-tricalcium phosphate
(b-TCP, an osteoconductive scaffold) for periodontal tissue
regeneration in human has recently been reported [12].
Fibroblast growth factor (FGF)-2 displays potent angiogenic
activity and mitogenic ability on mesenchymal cells. To date,
FGF-2 has been reported as efficacious in regenerating periodontal
tissue in models of artificial defect of periodontal tissue in beagles
and non-human primates (Macaca fascicularis) and in a model of
surgically created periodontitis in beagles [13–15].
The present clinical trial used hydroxypropylcellulose (HPC)-
based FGF-2 as the investigational agent. The purpose of this trial
was to both clarify the activity of FGF-2 to regenerate periodontal
tissue in periodontitis patients and to confirm drug safety. This
study was a randomized, double-blinded clinical trial (Phase II)
involving placebos and multiple dental facilities in compliance with
good clinical practice (GCP) guidelines, representing the first trial
to examine the efficacy and safety of FGF-2 in periodontitis
patients with concurrent control of dose-response relationships.
The periodontium that supports teeth displays a tissue structure
wherein the alveolar bone (hard tissue surrounding dental roots) is
covered by the gingiva (soft tissue), and ‘‘true regeneration’’ thus
involves the regeneration of both hard and soft tissues. To improve
tooth support, regenerating hard tissues including alveolar bone is
crucial. Hence, in the present study, under the assumption that
FGF-2 would regenerate both hard and soft tissues, the rate of
increase in alveolar bone height was established as the most
important outcome measure. Furthermore, to confirm soft-tissue
regeneration, the millimeter of clinical attachment level (CAL)
regained was added as a main outcome measure.
Including recruitment of subjects, the clinical trial was
performed from December 1, 2001 to September 29, 2004.
Methods
The Protocol for this trial and supporting CONSORT checklist
are available as supporting informations; see Checklist S1 and
Protocol S1.
This was a randomized, double-blinded, clinical trial of dose
responses including placebo comparison, involving 13 dental
facilities. Study protocols were approved prior to initiation of the
study by the institutional review boards of the respective
participating facilities.
1. Participants
Patients with periodontitis visiting any of the 13 dental
institutions listed in Table 1 were requested to participate. In
compliance with GCP guidelines, prospective 91 patients who
provided written informed consent underwent clinical inspection
and oral cavity diagnosis. Among 91 patients 80 patients who
satisfied the selection and exclusion criteria described in Tables 2
and 3 were finally registered. Each subject received a standard
initial preparation, including oral hygiene instruction, full-mouth
scaling and root planing before surgical treatment, to minimize
bacterial insult and reduce variability between lesions at baseline.
Using oral radiographs and periodontal tissue inspection results,
regions of investigation were determined as 2- or 3-walled vertical
periodontal tissue defects $3 mm apical to the remaining alveolar
bone crest.
2. Interventions, Design and Procedure
This trial employed recombinant human FGF-2 (Code No.
KCB-1; Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) produced
by genetic recombination that introduced the gene for human
FGF-2 into Escherichia coli. To improve the operability of drug
administration to the region of alveolar bone defect, before
administration we mixed freeze-dried FGF-2 with 3% HPC, a
colorless and viscid solution, and prepared the gel-like investiga-
tional drug for this clinical trial (Code No. KCB-1D). FGF-2
concentration in the investigational drug was then prepared to 0%
(placebo), 0.03%, 0.1% or 0.3% and administered to the region of
investigation within 2 h of preparation. Before the start and after
completion of investigational drug administration, a third-party
organization (University of Shizuoka, Shizuoka, Japan) measured
FGF-2 concentrations for each group to ascertain that FGF-2
concentrations in vials were accurate according to good manu-
facturing practice standards.
The clinical trial was conducted according to the schedule
shown in Figure 1. The 80 patients were registered at the
Registration Center (Adjust Co., Ltd., Sapporo, Japan) and then
randomly assigned to the following 4 groups: Group P, placebo
group administered HPC containing no FGF-2; Group L,
administered HPC containing 0.03% FGF-2; Group M, admin-
istered HPC containing 0.1% FGF-2; and Group H, administered
HPC containing 0.3% FGF-2.
All flap operations were performed in accordance with the
modified Widman procedure. The proposed surgical area was
anesthetized using local anesthetic. Following intracrevicular
incision, buccal and lingual full-thickness (mucoperiosteal) flaps
were elevated. Following reflection of the mucoperiosteal flap, all
granulation tissue associated with the bone defect was removed.
Subgingival soft and hard deposits on the root surface were
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ensure thorough degranulation and root planing. After that, 200
mL of investigational drug was administered to the bone defect
region described above. No specific root conditioning was
performed.
Next, at 1, 2 and 4 weeks after administration, the same clinical
inspections were performed as before administration, and anti-
FGF-2 antibodies in serum 2 and 4 weeks after administration
were measured. At 12, 24 and 36 weeks following administration,
standardized radiographs were taken, periodontal tissues were
inspected and subjective symptoms and objective findings were
observed. In addition, 6 patients from each of the groups were
randomly selected and blood samples were drawn. At 1, 2 and 4 h
after administering the investigational drug, FGF-2 concentrations
in serum were measured.
3. Randomization
An independent organization, the Registration Center (Adjust
Co., Ltd., Sapporo, Japan), was used to keep treatment allocation
inaccessible to any patients or other individuals involved in the
trial. The Registration Center created an allocation table in which
a block size of 4 cases per block was allocated to investigational
drugs comprising placebo (Group P), 0.03% FGF-2 (Group L),
0.1% FGF-2 (Group M) or 0.3% FGF-2 (Group H). According to
this allocation table, a label indicating the corresponding drug
number was attached to each and every vial of drug. After drugs
were allocated, the Registration Center sealed and kept the
allocation table in confidence until the clinical trial was completed.
Freeze-dried drugs for Groups P, L, M and H were indistinguish-
able based on appearance.
Investigators at each facility checked all inclusion and exclusion
criteria and registered patients one at a time by faxing patient
information obtained under informed consent to the Registration
Center. The center again checked the documents to make sure
that each subject had satisfied all inclusion and exclusion criteria,
then randomly allocated subjects as necessary to receive drugs
based on a single block consisting of one drug sample each from
Groups P, L, M, and H. The assigned drug numbers were then
faxed back to the investigators. The blind was not broken until this
clinical trial was completely finished.
Table 1. The 13 trial dental facilities and the investigators
Trial facilities Investigators Number of patients
Dental Hospital, Health Sciences University of Hokkaido Yusuke Kowashi 4
Medical and Dental Clinic, Health Sciences University of Hokkaido Takeo Fujii 9
Tohoku University Dental Hospital Hidetoshi Shimauchi 6
Aichigakuin University Dental Hospital Mitsuo Fukuda 7
Asahi University Dental Hospital Toshiaki Shibutani 6
Osaka University Dental Hospital Masahiro Kitamura 6
Okayama University Hospital of Dentistry Shogo Takashiba 11
Hiroshima University Hospital of Dentistry Hidemi Kurihara 3
Tokushima University Dental Hospital Jun-ichi Kido 12
Kyushu University Dental Hospital Takafumi Hamachi 2
Nagasaki University Hospital Attached School of Dentistry Yoshitaka Hara 6
Kagoshima University Dental Hospital Yuichi Izumi 8
Fukuoka Dental College Hospital Takao Hirofuji 0
80
doi:10.1371/journal.pone.0002611.t001
Table 2. Criteria for selecting subjects
1) Those diagnosed as having, from radiography and other results, 2- or 3-walled vertical intrabony defect as being measured at $3 mm apical to the remaining
alveolar bone crest
2) Those who have accomplished initial preparation and have been showing good compliance
3) Those with mobility of the tooth to investigate of Degree 2 or less and with width of attached gingiva for which the existing Guided Tissue Regeneration (GTR)
treatment is considered appropriate (Those with no width of keratinized gingival is not eligible)
4) Those for whom supportive periodontal treatment (SPT) is applicable, in accordance with usual post-operative procedures following flap operation and GTR
treatment
5) Those whose oral hygiene is well established and who are able to perform appropriate tooth brushing following instructions of the investigators and/or sub-
investigators after investigational drug administration
6) Those $20-years-old and ,65-years-old
7) Those who understand the purposes of the trial and are capable of making an independent decision to comply with trial requirements
8) Those who are able to visit their hospitals in accordance with the trial schedule
We selected those patients who met the criteria listed above, from those who the investigators and/or sub-investigators determined were in need of flap operation.
doi:10.1371/journal.pone.0002611.t002
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Main outcome measures prespecified in the study protocol
comprised: rate of increase in alveolar bone height; and millimeter
of CAL regained. In addition, we examined whether and to what
extent adverse events emerged for which causal relationships with
the investigational drug were not ruled out before breaking the
blind. We set rate of increase in alveolar bone height as the most
statistically important outcome (primary outcome). Probing depth
(PD), bleeding on probing (BOP), gingival index (GI), tooth
mobility (MO), gingival recession (REC), plaque index (PlI), and
width of keratinized gingiva (KG) were selected as secondary
outcome measures.
1) Standardized radiography for regions of investigation
Our geometrically standardized radiography employed dental
film (Kodak InSight Super Poly-Soft; Eastman Kodak Company,
New York, USA) and photograph indicators (Cone Indicator-II;
Hanshin Technical Laboratory, Nishinomiya, Japan) customized
with resin stents.
Five doctors specializing in dental radiology from the Depart-
ment of Oral Diagnosis at Tohoku University Graduate School of
Dentistry independently measured rate of increase in alveolar
bone height using the methods described in Figure 2. Errors
caused by slight variation in angulations of X-ray imaging were
corrected based on the distance between two immobile anatomical
Table 3. Criteria for excluding subjects
1) Those administered a calcium antagonist during the 4 weeks preceding administration of the investigational drug
2) Those in need of administration of adrenal cortical steroid (equivalent to.20 mg/day of Predonin) within 4 weeks after investigational drug
administration
3) Those scheduled to undergo a surgical operation in the vicinity of the tooth to investigate within 36 weeks after investigational drug
administration
4) Those with coexisting mental or consciousness disorder
5) Those with coexisting malignant tumour or history of the same
6) Those with coexisting diabetes (HbA1C .6.5%)
7) Those in an extremely poor nutritional condition (serum albumin concentration ,2 g/dL)
8) Those with $200 mL of blood drawn during the 4 weeks preceding investigational drug administration
9) Those administered another investigational drug during the 24 h preceding investigational drug administration
10) Those with coexisting disorder of the kidney, liver, blood and/or circulatory system (Grade 2 or above)
11) Those who are either pregnant, possibly pregnant or breast-feeding, or who hope to become pregnant during the period of the trial
12) Those with a previous history of hypersensitivity to a protein drug
13) Others who the investigators or sub-investigators determined as unsuitable for the trial
doi:10.1371/journal.pone.0002611.t003
Figure 1. Schedule of the clinical trial. We randomly allocated the 80 patients into 4 groups (n=20 each): 1) a placebo group (Group P); 2) a
group administered 0.03% FGF-2 (Group L); 3) a group administered 0.1% FGF-2 (Group M); and 4) a group administered 0.3% of FGF-2 (Group H). The
clinical trial was then conducted in accordance with the clinical trial schedule. We also measured FGF-2 concentrations in the blood serum of 6
patients randomly chosen from each of the 4 groups, before and then 1 h, 2 h and 4 h after administration of the investigational drug.
doi:10.1371/journal.pone.0002611.g001
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same image was then selected for efficacy analysis. Before making
measurements in the present study, X-ray images were read to
measure intra- and interexaminer variations. Each of the 5 doctors
measured the same sample 5 times to calculate coefficients of
variation. The results showed that intra- and interexaminer
coefficients of variation were both 3%, confirming the absence
of marked variations.
2) Inspection of periodontal tissue around the tooth under
investigation
We measured the items shown in Table 4 at 6 positions
(mesiobuccal, buccal, distobuccal, mesiolingual, lingual and
distolingual) around each tooth under investigation.
All examiners used PCP-UNC-15 periodontal probes (Hu-
Friedy, Chicago, IL). We held meetings with each investigator
from all of the participating facilities. In addition, a start-up
meeting in which all investigators from a single facility participated
was held at each facility. In these meetings, the protocol for this
clinical trial was confirmed and clinical evaluations were
standardized between facilities. In all facilities, the same person
(MW) explained the detailed methods of probing inspections to all
investigators and confirmed reproducibility and consistency for
each investigator. Furthermore, prior to initiating baseline
measurements, intra- and interexaminer calibrations were per-
formed on patients at each facility to ensure reproducibility and
consistency by each investigator. Each patient was examined by
the same examiner at every recall visit throughout this clinical
trial.
5. Safety evaluation
1) Observation of subjective symptoms and objective findings
Medical findings for both the oral cavity and whole body were
confirmed by interview and visual inspection.
2) Clinical inspections
A clinical testing company (SRL Medisearch Inc., Tokyo,
Japan) measured the inspection items (see Table S1 of supporting
items). In cases where we discovered unusual changes in any of the
clinical inspection values listed within 4 weeks after administration
of the investigational drug, a follow-up survey was conducted.
3) Measurement of anti-FGF-2 antibody levels in serum
The Pharmacokinetics Department of Kaken Pharmaceutical
Co., Ltd. measured levels of anti-FGF-2 antibody (IgG) in serum
using ELISA.
4) Measurement of FGF-2 concentration within serum
The Metabolism Research Department of Kaken Pharmaceu-
tical Co., Ltd. measured FGF-2 concentrations in serum using
ELISA.
6. Sample size calculation
The effect of a combination drug comprising recombinant
human PDGF-BB and IGF-I in humans on periodontal
regeneration has already been reported [19]. In PDGF-BB/IGF-
I-treated subjects (n=16), mean (6standard error of mean) bone
fill was 18.567% for control sites (surgery alone) and 42.369% for
PDGF-BB/IGF-I sites with a mean difference of 23.8%. Assuming
a rate of increase for placebo control of 20% (standard deviation,
28%) in alveolar bone of the defect region, the planned sample size
Figure 2. Measured points of alveolar bone height using standardized radiographs. Standardized dental radiographs taken before and
after FGF-2 administration in one subject (a 29-year-old man) given 0.3% FGF-2. Points A, B, C and D represent the cementoenamel junction, apex,
remaining alveolar bone crest and bottom of the bone defect, respectively. The examiners measured tooth axis heights between Points A and B,
Points A and C, and Points A and D on the X-ray for each patient. To adjust for slight errors due to imaging, measurements for 5 examiners were
multiplied by A-B ratio of before to after administration to correct A-B, A-C and A-D after administration (adjusted A-B, A-C and A-D, respectively).
Rate of increase in alveolar bone height was derived from the following calculation formula. [(A-D before administration) - (adjusted A-D after
administration)] by C-D before administration. On this radiography, C-D before administration, A-D before administration and, adjusted A-D after
administration measured 9.00 mm, 12.80 mm and 5.93 mm, respectively. These values assigned to the above formula, we obtained the rate of
increase in alveolar bone height as follows. The rate of increase in alveolar bone height (%)=100(12.80–5.93)/9.00=76.35.
doi:10.1371/journal.pone.0002611.g002
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any clinically relevant treatment difference of 30% at a two-tailed
significance level of 0.05.
7. Statistical methods
For analysis, we employed SAS version 8.2 software (SAS
Institute Inc., Carey, North Carolina, USA). The level of statistical
significance was set at p,0.05 in advance. Data analysis covered
those patients administered the randomly allocated investigational
drugs. In analyses concerning efficacy, those patients found to
have either 1- or 4-walled intrabony defect during surgery after
allocation were excluded. To statistically compare the 3 dose
groups in terms of rate of increase in alveolar bone mass with the
placebo group, the Dunnett option was used based on the Mixed
procedure in the SAS system, in which adjusted p-values were
computed for multiple comparisons, and analysis for rates of
increase during follow-up was performed using repeated-measures
analysis of variance with the Mixed procedure.
Results
1. Patient characteristics at the beginning of the trial
(baseline characteristics)
Figure 3 shows flow of patients through the study. The 91
patients screened as subjects were consenting periodontitis patients
for whom periodontal tissue regeneration therapy was indicated by
investigators based on these criteria among a large number of
potential subjects. Following the exclusion of 11 of these 91
patients, a final total of 80 patients were enrolled as subjects in the
present clinical trial. The 11 patients were excluded due to findings
on clinical inspection that could not have been determined by
investigators during clinical periodontal diagnosis, or due to
withdrawal of consent to participate. The 80 patients were then
randomly assigned to 4 groups of 20 patients each. Table 5 shows
the baseline characteristics of patients.
2. Evaluation of efficacy
Rate of increase in alveolar bone height at 12, 24 and 36 weeks
after FGF-2 administration are shown in Table 6. A significant
difference (p=0.021) was only identified between Group P and
Group H at 36 weeks. The detailed data at 36 weeks are shown in
Fig. 4 and Table 7. Adjusted mean differences from Group P were
also calculated as least square mean (LSMean) differences based
on two-way analysis of variance or analysis of covariance (data not
shown). Adjusted mean differences for gender, site of investiga-
tional drug administration (maxilla or mandible), CAL, REC, GI,
MO, PlI and type of bone defect mostly resembled raw mean
differences and the lower 95% confidence limits of LSMean
difference (Group P vs. H) was above zero (0,lower 95%
confidence limit). These results indicate that baseline characteristic
imbalances between groups had no influence on evaluation of
efficacy. Regarding the CAL regained (Table 8), REC, KG, MO
and PlI (see Table S2 of supporting items), no significant
differences existed between the 4 groups. Although PD, GI and
BOP prevalence all decreased with time following periodontal
surgical treatment in the 4 groups (see Table S3 of supporting
items), no significant differences were noted between these groups.
Two-way analysis of variance was used to assess facility
differences in the 4 groups in the rate of increase in alveolar bone
height, revealing no significant treatment-by-facility interaction
(p=0.795). This suggests that no marked facility differences
existed with respect to response.
3. Safety evaluation
Major adverse events for which causal relationships with the
investigational drug were not ruled out before breaking the blind
included positive urinary albumin, increased urinary excretion of
b2-microglobulin and N-acetyl-beta-D-glucosamidase, increased
serum creatine kinase and C-reactive protein and increased cases
of hypersensitive dentine (see Table S4 of supporting items).
Frequencies of these adverse events were independent of FGF-2
concentration. No serious adverse events were observed through-
out the clinical trial period. A possible association was also
considered between frequency of adverse events observed during
the trial and the investigational drug administration. None of the
adverse events exhibited a strong causal relationship or were
severe, and except for one case, all events resolved without any
special treatment. For each group, the presence/absence and
frequency of adverse events were calculated. Fisher’s exact test
showed that group allocations exhibited no association to the
presence/absence of adverse events (p=0.469). In addition,
during the inspection following FGF-2 administration (Fig. 1), no
FGF-2 or anti-FGF-2 antibodies were detected in the serum of any
patients.
Discussion
Originally isolated from bovine hypophysis in the 1970s, FGF-2
is a protein with a molecular weight of 17,000 that acts to promote
proliferation of fibroblasts. Researchers have isolated, refined and
Table 4. Periodontal tissue inspection
1) Clinical attachment level (CAL): A stent was prepared for each subject. Using as the control point the cementoenamel junction or margin of the restorative
material, distance between the control point and bottom of the gingival sulcus was measured for each test subject, using the same periodontal probe.
2) Probing depth (PD): Simultaneously with CAL measurement, we measured distance from the gingival margin to the bottom of the gingival sulcus for each
subject using the same periodontal probe.
3) Bleeding on probing (BOP; + or 2): The presence of bleeding was checked 10 s after probing.
4) Gingival index (GI): GI was determined as described by Lo ¨e and Silness.
16
5) Mobility of tooth (MO): MO was determined as described by Miller.
17
6) Recession of gingiva (REC): Using as the control point the cementoenamel junction or margin of the restorative material, distance between the control point and
gingival margin was measured for each subject, using the same periodontal probe.
7) Plaque index (PlI): PlI was determined as described by Silness and Lo ¨e.
18
8) Width of keratinized gingiva (KG): The shortest distance between the coronal gingival margin and mucogingival junction was measured for each subject, using
the same periodontal probe.
doi:10.1371/journal.pone.0002611.t004
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biological activities of the protein. As yet, many studies have
reported that FGF-2 stimulates proliferation of numerous kinds of
cells, including not just fibroblasts, but also vascular endothelial,
vascular smooth muscle, neuroectodermal, osteoblast, cartilage
and epidermal cells. The protein is now known to be deeply
involved in cell proliferation and differentiation and also in control
of extracellular matrix generation during the processes of tissue
generation and wound healing [20–25]. Many recent reports in
the field of regenerative medicine have described the use of
cytokines as ‘‘signaling molecules’’, stimulating adequate prolifer-
ation and differentiation of tissue stem cells. Among those
cytokines, FGF-2 is winning attention from researchers due to
activity in promoting proliferation of mesenchymal stem cells
while maintaining multilineage potential [6]. The protein has
already been utilized in a human intractable ulcer-curing drug
(Fiblast Spray; Kaken Pharmaceutical Co., Ltd.) for more than 4
years.
We have already studied the stimulation of periodontal tissue
regeneration by FGF-2 in animal models and believe that the
protein represents a major candidate for a periodontal tissue-
regenerating agent. This is based on stimulation of proliferation
for both kinds of cell groups that rebuild hard and soft tissues along
with strong angiogenic activity, which is indispensable in tissue
regeneration. Animal tests have revealed that in artificial models of
periodontal tissue defect in beagles [13,15] and non-human
primates (M. fascicularis) [14], FGF-2 significantly stimulates
neogenesis of alveolar bone, periodontal ligament and cementum,
without invoking abnormal effects such as down-growth of the
gingival epithelia, resorption of the dental root or ankylosis.
Based on effective concentrations of FGF-2 for periodontal
tissue regeneration in animal trials, in addition to the results of our
Phase I trial in which FGF-2 was administered intravenously to
healthy adult humans, we determined the concentrations and
doses administered to periodontal regions of patients in the present
clinical trial. More specifically, the results of testing with artificial
defect models of periodontal tissue in beagles led us to estimate
that an effective FGF-2 concentration for stimulation of periodon-
tal tissue regeneration was 0.03–0.3%. This range of concentra-
tions was therefore applied in the present clinical trial. We selected
200 mL as the dose, considering that this was good enough to work
on the defect region of periodontal tissue. In addition, preclinical
trial results have suggested that the maximum quantity of
administered FGF-2 to enter the circulation in the present trial
herein would be around 1.2 mg/body, less than the 30 mg/body
for which safety was confirmed in our Phase I trial. The 91
patients screened as subjects and a final total of 80 patients were
enrolled as subjects. The patient characteristics were almost
similar among groups. However, we understand that we could not
perfectly eliminate biasing influences of patient characteristics in
this study and a larger scale trial is needed in the future.
In evaluating efficacy, we surveyed 74 cases of 2- or 3-walled
intrabony defect that satisfied the selection criteria. To evaluate
periodontal tissue regeneration, evaluating fibrous attachment
accompanied by neogenesis of alveolar bone and cementum is
important. Rate of increase in alveolar bone height observed in
close proximity to the dental root was measured as a prespecified
primary outcome in this clinical trial.
Use of 0.3% FGF-2 stimulated 58.6% regeneration, which was
at least comparable with the previous results within 9 months after
Figure 3. Flow of patients through the study.
doi:10.1371/journal.pone.0002611.g003
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ence was identified between Groups P and H in terms of
millimeter increments (p=0.132). To confirm the efficacy of the
investigational drug using more conventional methods, data in
both % and millimeter increments were used to calculate sample
size for the next late Phase II trial. In addition, the minimum
clinically effective dose will need to be assessed and determined in
a future clinical study involving more patients.
Interestingly, no significant difference was observed between the
4 groups in the millimeter of CAL regained, with all groups
scoring around 2 mm (see Table S2 of supporting items). The
CAL regained following periodontal surgery is derived from the
sum of epithelial and fibrous attachments. If periodontal tissue
regeneration accompanied by neogenesis of the alveolar bone and
cementum is stimulated, fibrous attachment reproducing the
natural anatomical morphology is achieved. However, the
Table 5. Patient characteristics
Item Classification Group P Group L Group M Group H
Numbers of patients 20 19 20 20
Sex (% of patients) Male 55.0 36.8 25.0 35.0
Female 45.0 63.2 75.0 65.0
Age (years) Mean (SD) 49.2 (8.9) 46.2 (11.1) 46.8 (10.3) 47.7 (10.5)
Coexisting disease (% of patients) No 70.0 57.9 75.0 85.0
Yes 30.0 42.1 25.0 15.0
Previous history No 75.0 73.7 60.0 60.0
Yes 25.0 26.3 40.0 40.0
Smoking habit No 75.0 89.5 80.0 70.0
Yes 25.0 10.5 20.0 30.0
Region of administration (Major classification) (% of patients) Maxilla 40.0 57.9 55.0 60.0
Mandible 60.0 42.1 45.0 40.0
Region of administration (Minor classification) (% of patients) Anterior tooth 25.0 21.1 25.0 30.0
Premolar 35.0 42.1 40.0 40.0
Molar 40.0 36.8 35.0 30.0
Depth of bone defect at operation (mm) Mean (SD) 4.7 (1.5) 4.8 (2.4) 4.6 (1.7) 5.7 (2.6)
Classification of bone defect (% of patients) 1-walled 5.0 0.0 5.0 10.0
2-walled 50.0 47.4 70.0 50.0
3-walled 40.0 47.4 25.0 30.0
4-walled 0.0 0.0 0.0 5.0
2/3-walled 0.0 5.3 0.0 5.0
1/2-walled 5.0 0.0 0.0 0.0
Treatment to tooth of investigation (% of patients) No 60.0 57.9 55.0 55.0
Yes 40.0 42.1 45.0 45.0
Existent of dental pulp (% of patients) No 15.0 15.8 20.0 25.0
Yes 85.0 84.2 80.0 75.0
Clinical attachment level (mm) Mean (SD) 9.3 (2.2) 8.4 (2.7) 8.4 (2.8) 8.3 (3.0)
Probing depth (mm) Mean (SD) 5.7 (1.2) 5.4 (1.6) 5.1 (2.0) 5.8 (1.7)
Recession (mm) Mean (SD) 2.4 (1.8) 2.1 (1.5) 2.2 (2.3) 1.7 (1.5)
Width of keratinized gingival (mm) Mean (SD) 4.9 (2.1) 4.3 (1.9) 4.5 (2.2) 5.3 (2.7)
Gingival bleeding index (% of patients) 2 10.0 15.8 20.0 5.0
+ 90.0 84.2 80.0 95.0
Gingival index (% of patients) 0 35.0 21.1 25.0 10.0
1 30.0 47.4 40.0 45.0
2 35.0 31.6 35.0 45.0
Mobility of tooth (% of patients) 0 65.0 57.9 50.0 40.0
1 35.0 36.8 50.0 55.0
2 0.0 5.3 0.0 5.0
Plaque index (% of patients) 0 50.0 42.1 80.0 60.0
1 35.0 57.9 20.0 30.0
2 15.0 0.0 0.0 10.0
doi:10.1371/journal.pone.0002611.t005
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surgery has been shown to be due to epithelial attachment
unaccompanied by alveolar bone regeneration [28–31]. We have
previously conducted an animal study using non-human primates
and reported that at the FGF-2 administration site, down-growth
of gingival epithelial cells was suppressed to achieve fibrous
attachment accompanied by neogenesis of the alveolar bone and
cementum [14]. In the present study, no significant differences in
CAL regained were seen between Group P (conventional
periodontal surgery) and the three FGF-2 groups (Table 8). Based
on the results of the above-mentioned preclinical study, we deduce
that differences may exist between Group P and the three FGF-2
groups in histological ratio of fibrous and epithelial attachments
achieving CAL acquisition. Confirmation of the nature of healing
tissue requires histological evaluation in a future study.
PD, BOP, GI, MO, REC and KG are generally used to assess
pathology in periodontal disease. These parameters do not directly
assess the efficacy of FGF-2 in periodontal tissue regeneration, and
were selected in the present study as secondary outcome measures
to ascertain whether FGF-2 would cause abnormal periodontal
healing following periodontal surgery. The fact that no significant
differences among these secondary outcome measures for the 4
groups showed that FGF-2 administration did not cause abnormal
healing of periodontium following periodontal surgery. Further-
more, frequency of PD, GI, and BOP all dropped over time in all
groups after periodontal surgical treatment. These findings show
that we can expect FGF-2 administration to provide a therapeutic
process similar to that of the conventional flap operation, in
addition to the healing outcome of periodontal tissue regeneration.
Yet another observation was the lack of recognisable difference in
changes to REC and KG, which accompanies periodontal surgical
treatment, between Group P and the other 3 groups receiving
FGF-2 administration. This confirms that FGF-2 administration
does not cause peculiar gingival recession or reduce keratinized
gingiva. PlI offers a parameter for assessing the amount of plaque
causing periodontal disease, and since the degree of plaque
deposition can affect the prognosis of periodontal surgery, this
parameter was also selected as a secondary outcome measure. In
this clinical study, no significant intergroup differences were seen
in PlI. Moreover, radiography was performed for 67 patients who
willingly and positively responded to our ‘‘recall’’ for imaging
between week 83 and 132 (inclusive) after administration of
investigational drugs (Group P, n=19; Group L, n=15; Group
M, n=18; Group H, n=16). Among these 67 patients, no cases
suggested an abnormal increase in alveolar bone exceeding the
cementoenamel junction or an equivalent control point or
ankylosis (data not shown).
The periodontal ligament comprises heterogenous cell popula-
tions and researchers have predicted the existence of some
progenitor cells that can differentiate into cementoblasts or
osteoblasts [32–34]. A recent study reported that some cells within
the ligament express STRO-1 and CD146 mesenchymal stem cell
markers. Such cells, according to the study, differentiate into
cementoblast-like cells, adipocytes and collagen-forming cells. Our
previous in vitro studies have clarified that FGF-2 facilitates
proliferation while maintaining the differentiation of human
periodontal ligament cells (HPDLs). In addition, we now know
that the protein does not just stimulate angiogenesis, an action
indispensable in the regeneration of tissue, but also increases the
production of various types of extracellular matrix from HPDLs
[21,35–37]. In short, FGF-2 creates a local environment suitable
for the regeneration of periodontal tissue through the activities
described above, as part of the mechanism by which regeneration
of periodontal tissue is stimulated.
In our clinical trial, to identify adverse events from FGF-2
administered to a particular region of periodontal tissue, we
conducted an interview and visual inspection to check the whole
body of the patient, checked oral cavity findings and performed
clinical inspection. No relationships were identified between
Figure 4. Rates of increase in alveolar bone height in cases of
2- and 3-walled intrabony defects. We compared rates of increase
in alveolar bone height at 36 weeks after FGF-2 administration among
Group P (19 placebo cases), Group L (19 cases administered 0.03% FGF-
2), Group M (19 cases administered 0.1% FGF-2) and Group H (17 cases
administered 0.3% FGF-2). This figure shows mean increase rates (%)
and standard deviations of alveolar bone height. While no significant
difference was observed between Groups L and M and P, Group H
showed significantly increased (p=0.021) alveolar bone height in the
bone defect region compared to Group P.
doi:10.1371/journal.pone.0002611.g004
Table 6. Changes with time in alveolar bone height
Group P (n=19) Group L (n=19) Group M (n=19) Group H (n=17)
rate of increase (%) 12 weeks 6.90 (20.12) 2.03 (18.79) 20.82 (33.1) 13.86 (33.03)
24 weeks 17.44 (28.48) 12.33 (27.50) 12.59 (23.67) 35.58 (40.35)
36 weeks 23.92 (27.52) 20.19 (38.09) 29.39 (37.71) *58.62 (46.74)
millimeter increase 12 weeks 0.28 (0.80) 0.07 (0.58) 0.15 (0.71) 0.55 (1.37)
24 weeks 0.67 (1.25) 0.38 (0.97) 0.53 (0.71) 1.21 (1.57)
36 weeks 0.95 (1.26) 0.54 (1.26) 1.06 (1.16) 1.85 (1.75)
Mean and standard deviations are shown.
*A significant difference (p=0.021) was only identified between Group P and Group H at 36 weeks in rate of increase in
alveolar bone height.
doi:10.1371/journal.pone.0002611.t006
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adverse events (see Table S4 of supporting items). Although some
adverse events did emerge in patients administered FGF-2, no
relationship was recognizable between frequency of these events
and FGF-2 concentrations. In addition, the same adverse events
also emerged in the placebo group. Those effects are therefore not
specific to groups administered FGF-2 and do not appear
attributable to the drugs administered. Another reason why we
consider that FGF-2 administered locally to periodontal tissue
seldom travels through the whole body to create adverse drug
reactions is that the protein was undetectable in serum after drug
administration. Furthermore, no patients displayed increased
levels of anti-FGF-2 antibody after administration, suggesting that
FGF-2 is free from antibody production, an adverse drug reaction
often seen with other proteinaceous agents. In short, none of the
results of this particular clinical trial suggest any clinical problems
concerning the safety of administering FGF-2 to patients with
periodontitis. One more piece of evidence supporting the high
safety of FGF-2 applied locally to periodontal tissue is that this
therapy has already been used for more than 5 years as a remedy
for intractable ulcers (Fiblast spray).
Periodontitis shortens the life of teeth and can thus reduce QOL
in middle-aged to elderly individuals [4]. To maintain and
promote oral health, new therapies must be established for safe
and efficient regeneration of periodontal tissue. Cytokine therapy
has thus been winning attention for the last decade [6–15,19].
However, few double-blinded clinical trials have used multiple
facilities in compliance with GCP guidelines to confirm the
efficacy of a single cytokine alone as a stimulator of periodontal
tissue regeneration. In the present clinical trial, 0.3% FGF-2
improved CAL by about 2 mm at 36 weeks from base. And more
importantly, rate of increase in bone height observed in close
proximity to the dental root was significantly improved in 0.3%
FGF-2 treatment group compared to placebo group at 36 weeks.
These findings were clinically interpreted that some efficacy could
be expected from FGF-2 in stimulating regeneration of periodon-
tal tissue. Thus, we concluded in this study that FGF-2 therapy can
be efficacious in regenerating periodontal tissue. However, an
important limitation of this study is the small sample size of the
trial. This trial is still preliminary, and several trials need to be
performed before FGF-2 drug can be placed on the market. In
future, we plan to clarify the efficacy of FGF-2 drug, determine the
optimal dose for clinical use and confirm in more detail the safety
of FGF-2 in a large Phase II study. And then Phase III will be
performed to confirm the efficacy and safety of the invitational
drug.
(This clinical trial was conducted at the request of Kaken
Pharmaceutical Co., Ltd.)
Supporting Information
Checklist S1 CONSORT Checklist.
Found at: doi:10.1371/journal.pone.0002611.s001 (0.04 MB
DOC)
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0002611.s002 (0.11 MB
DOC)
Table 7. Changes in alveolar bone height at 36 weeks
Group P (n=19) Group L (n=19) Group M (n=19) Group H (n=17)
rate of increase (%) Mean (SD) 23.92 (27.52) 20.19 (38.09) 29.39 (37.71) 58.62 (46.74)
Mean differences 23.73 5.47 34.7
from Group P (95%CI) (228.22–20.77) (219.02–29.97) (9.50–59.91)
Adjusted p value* 0.981 0.945 0.021
millimeter increase Mean (SD) 0.95 (1.26) 0.54 (1.26) 1.06 (1.16) 1.85 (1.75)
Mean differences 20.41 0.11 0.90
from Group P (95%CI) (21.24–0.42) (20.69–0.91) (20.13–1.92)
Adjusted p value* 0.678 0.990 0.132
*Adjusted for multiple comparisons based on Dunnett’s test.
doi:10.1371/journal.pone.0002611.t007
Table 8. Clinical Attachment Level (CAL) regained at 36 weeks
Group P (n=19) Group L (n=19) Group M (n=19) Group H (n=17)
mm of CAL regained Mean (SD) 2.63 (1.54) 2.00 (2.08) 2.02 (2.08) 2.18 (1.33)
Mean differences 20.63 20.61 20.46
From Group P (95%CI) (21.84–0.57) (21.81–0.60) (21.43–0.53)
Adjusted p value* 0.573 0.604 0.792
% of CAL regained Mean (SD) 29.65 (17.00) 24.03 (25.31) 24.20 (28.27) 29.69 (23.14)
Mean differences 25.62 25.45 0.04
from Group P (95%CI) (219.81–8.60) (220.79–9.90) (213.61–13.70)
Adjusted p value* 0.810 0.823 1.000
*Adjusted for multiple comparisons based on Dunnett’s test.
doi:10.1371/journal.pone.0002611.t008
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Found at: doi:10.1371/journal.pone.0002611.s003 (0.03 MB
DOC)
Table S2 Changes in periodontal tissue. Mean and standard
deviations are shown. *Data at 36 weeks were missing for 1 patient
in Group M.
Found at: doi:10.1371/journal.pone.0002611.s004 (0.07 MB
DOC)
Table S3 Changes in periodontal tissue. All of data at 36 weeks
were missing for 1 patient in Group M. Data for MO were missing
at 12 weeks for each patient in Groups P and H, at 24 weeks in
Group H and at 36 weeks in Group H.
Found at: doi:10.1371/journal.pone.0002611.s005 (0.07 MB
DOC)
Table S4 List of adverse drug reactions. *Pains experienced by 1
patient in Group M required therapy, and the patient began to
experience pain at the surgical site starting 8 days after
administration that resolved 35 days after administration with
the use of drugs such as cefcapene pivoxil hydrochloride, lysozyme
hydrochloride, rebamipide and loxoprofen sodium.
Found at: doi:10.1371/journal.pone.0002611.s006 (0.04 MB
DOC)
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